EGFR and glioblastoma: In particular, by evaluating mutations in isocitrate dehydrogenases (IDH) 1 and 2, ATRX chromatin remodeler, tumor protein p53 (TP53), telomerase reverse transcriptase (TERT), codeletion in 1p/19q, homozygous deletion in cyclin-dependent kinase inhibitors 2A and 2B (CDKN2A−B), gain in epidermal growth factor receptor (EGFR) and/or chromosome 7 and loss of chromosome 10 (7+/10−), adult-type diffuse gliomas can be classified in astrocytoma (IDH-mutant), oligodendroglioma (IDH-mutant and 1p/19q-codeleted), and glioblastoma (IDH-wildtype) [6].